Plasma anti Xa-levels in obese patients undergoing bariatric surgery and receiving low molecular weight heparins for thromboprophylaxis.

Plasma anti Xa-levels in obese patients undergoing bariatric surgery and receiving low molecular weight heparins for thromboprophylaxis. - Anti-Xa levels in the obese.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON37877

Enrollment

Registered

2012-01-05

Start date

2012-07-18

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

blood clotting venous thromboembolism

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: a. All patients who have undergone bariatric surgery (laparoscopic gastric banding, duodenal switch procedure, sleeve gastrectomy, gastric bypass) recently and who are receiving enoxaparin 40 mg twice daily as noted in the protocols of the hospital b. Adults> 18 years old c. Obtained informed consent

Exclusion criteria

Exclusion criteria: Patients with at least one of the following criteria will be excluded: a. enoxaparin dosage different from that specified in the protocol (40 mg twice daily) b. receiving a thrombolytic agent c. antithrombin III deficiency d. renal insufficiency (estimated Glomerular Filtration Rate

Design outcomes

Primary

Measure	Time frame
Anti-Xa peak concentration and correlation with body weight.	—

Secondary

Measure	Time frame
nvt	—

Countries

Netherlands

Outcome results